Author

P. Msaouel

h-index 5 View on Semantic Scholar

We have 3 of 61 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity

Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...

N. Zacharias, Eric S Rupe, Xinyue Chen et al. · Clinical Cancer Research · 0 citations

Meta-analysis Sep 2026

Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)

Abstract Designing phase III oncology trials to demonstrate overall survival (OS) superiority may be challenging due to sample size, follow-up time, resources, and costs as compared to trials evaluating intermediate endpoints, which may or may not be reliable surrogates of OS. In this study, we investigate at scale the...

A. Sherry, N. Meimoun, A. Miller et al. · The Oncologist · 0 citations

Open access Sep 2026

25 Phase II Trial of Sacituzumab Tirumotecan in Patients with SMARCB1-Deficient Renal Medullary Carcinoma Previously Treated with at Least One Prior Line of Therapy: STaRMC Trial (NCT07438626)

It is hypothesized that sacituzumab tirumotecan will produce a potent and durable antitumor response in patients with RMC who develop progressive disease on at least one prior line of therapy.

P. Msaouel, Rebecca S. Slack-Tidwell, R. Sheth et al. · The Oncologist · 0 citations